Fc epsilon RI/FCER1A antibody (AA 85-172) (FITC)

Catalog No. ABIN2451978

This anti-Fc epsilon RI/FCER1A antibody is a Mouse Monoclonal antibody detecting Fc epsilon RI/FCER1A in FACS, IHC, IF and ICC. Suitable for Human. This Primary Antibody has been cited in 6+ publications.

Quick Overview for Fc epsilon RI/FCER1A antibody (AA 85-172) (FITC) (ABIN2451978)

Target: Fc epsilon RI/FCER1A (FCER1A) (Fc Fragment of IgE Receptor Ia (FCER1A))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Fc epsilon RI/FCER1A antibody is conjugated to FITC

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: CRA2

Product Details anti-Fc epsilon RI/FCER1A Antibody (FITC)

Binding Specificity: AA 85-172

Characteristics: The IgG fraction was purified from serum free culture medium of mouse hybridoma (CRA2) by propriety chromatography under mild conditions.

Purification: Purified

Sterility: Sterile filtered

Immunogen: AA 85-172 of FcepsilonR1alpha

Isotype: IgG1 kappa

Application Details

Application Notes: 1) FACS
2) Immunohistochemistry and immunocytochemistry
3) Inhibition of binding of IgE with FcepsilonR1alpha.
Titration of IgE-bound fraction of the FcepsilonR1alpha using CRA1 and CRA2 antibodies

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS ( pH 7.4), 50 % glycerol

Preservative: Azide free

Storage: -20 °C

References for anti-Fc epsilon RI/FCER1A antibody (FITC) (ABIN2451978)

Takai, Yuuki, Iwamoto-Yasue, Okumura, Ra: "Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions." in: Bioscience, biotechnology, and biochemistry, Vol. 64, Issue 9, pp. 1856-67, (2001) (PubMed).

Takai, Okumura, Ra: "Direct expression of the extracellular portion of human FcepsilonRIalpha chain as inclusion bodies in Escherichia coli." in: Bioscience, biotechnology, and biochemistry, Vol. 65, Issue 1, pp. 79-85, (2001) (PubMed).

Goto, Soma, Ra, Kawa, Kubota, Mizoguchi: "Enhanced expression of the high-affinity receptor for IgE (Fc(epsilon)RI) associated with decreased numbers of Langerhans cells in the lesional epidermis of atopic dermatitis." in: Journal of dermatological science, Vol. 27, Issue 3, pp. 156-61, (2001) (PubMed).

Hasegawa, Pawankar, Suzuki, Nakahata, Furukawa, Okumura, Ra: "Functional expression of the high affinity receptor for IgE (FcepsilonRI) in human platelets and its' intracellular expression in human megakaryocytes." in: Blood, Vol. 93, Issue 8, pp. 2543-51, (1999) (PubMed).

Hakimi, Seals, Kondas, Pettine, Danho, Kochan: "The alpha subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding." in: The Journal of biological chemistry, Vol. 265, Issue 36, pp. 22079-81, (1991) (PubMed).

Ra, Jouvin, Blank, Kinet: "A macrophage Fc gamma receptor and the mast cell receptor for IgE share an identical subunit." in: Nature, Vol. 341, Issue 6244, pp. 752-4, (1989) (PubMed).

Target Details for Fc epsilon RI/FCER1A

Target: Fc epsilon RI/FCER1A (FCER1A) (Fc Fragment of IgE Receptor Ia (FCER1A))

Background: FcεR1alpha is subunit of the high affinity receptor for IgE to which IgE directly binds. FcεR1alpha is a tetrameric complex consisting of one alpha, one beta and two γ subunits. The latter two are required for signal transduction activity. The FcεR1 complex plays an important role in triggering allergic responses. The CRA2 (AER24) monoclonal antibody reacts with the FcεR1alpha subunit on a region that overlaps the region of the IgE binding site, thus it competes with IgE for the receptor binding. Since the CRA1 (AER37) monoclonal antibody reacts with the site different from the IgE binding site on FcεR1alpha, it does not compete with IgE for the receptor binding. Combining the two antibodies, one can quantitatively measure the amounts of the IgE-bound FcεR1alpha.

UniProt: P12319

Pathways: Fc-epsilon Receptor Signaling Pathway, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process